STOCK TITAN

AMARANTUS BIOSCIENCE HLDG - $AMBS STOCK NEWS

Welcome to our dedicated page for AMARANTUS BIOSCIENCE HLDG news (Ticker: $AMBS), a resource for investors and traders seeking the latest updates and insights on AMARANTUS BIOSCIENCE HLDG stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMARANTUS BIOSCIENCE HLDG's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMARANTUS BIOSCIENCE HLDG's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
AMARANTUS BIOSCIENCE HLDG

OTC:AMBS

AMBS Rankings

AMBS Stock Data

63.04k
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
New York

About AMBS

amarantus bioscience holdings (otcqb: ambs) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. ambs owns the rights to engineered skin substitute program, a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ess is entering phase 2 clinical studies under a crada agreement with the us army, and is also preparing a pivotal development program for rare pediatric disease giant congenital melanocytic nevi. ambs' also has licensing rights to eltoprazine, a phase 2b-ready small molecule indicated for parkinson's disease levodopa-induced dyskinesia, adult adhd and alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor and is developing manf-based products as treatments for brain and ophthalmic disorders. ambs' diagnostics division